Endo Health Reaches New 52-Week High (ENDP)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Endo Health Solutions (Nasdaq: ENDP) hit a new 52-week high Friday as it is currently trading at $38.34, above its previous 52-week high of $38.32 with 314,249 shares traded as of 10:26 a.m. ET. Average volume has been 2.3 million shares over the past 30 days.

Endo Health has a market cap of $4.04 billion and is part of the health care sector and drugs industry. Shares are up 37.1% year to date as of the close of trading on Thursday.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Endo Health as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and weak operating cash flow. You can view the full Endo Health Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds